Holen Sie sich die Stockscreener-App
5.09
3.23%
-0.17
Handel nachbörslich:
5.10
0.010
+0.20%
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - PR Newswire
Aug Wrap: Does Aardvark Therapeutics Inc have a competitive edge2026 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Cresset Asset Management Invests $1.95M in Aardvark Therapeutics - National Today
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
New Highs: Should I trade or invest in Aardvark Therapeutics Inc2025 Market Outlook & Low Risk High Win Rate Picks - baoquankhu1.vn
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves - simplywall.st
NOTICE TO DISREGARD -- Pomerantz LLP - GlobeNewswire Inc.
A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial - Yahoo Finance
uniQure loses $1B after FDA rejects Huntington’s data, Aardvark falls on cardiac safety signal, and more - BioCentury
What's Going On With Aardvark Therapeutics Stock On Wednesday? - Bitget
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
AARDAardvark Therapeutics Latest Stock News & Market Updates - Stock Titan
Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark ... - Bluefield Daily Telegraph
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Why AMTD Digital Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Sahm
Dow Falls 150 Points; ISM Manufacturing PMI Edges Lower In February - Sahm
Aardvark Therapeutics, Inc. (AARD) Receives Hold Rating Amid Market Volatility - 富途牛牛
Twilio To Rally More Than 32%? Here Are 10 Top Analyst Forecasts For Monday - Sahm
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101 - simplywall.st
Aardvark Therapeutics stock plunges after trial pause By Investing.com - Investing.com Canada
Aardvark Therapeutics stock plunges after trial pause - Investing.com South Africa
AARD Stock Sees Downgrade as RBC Capital Lowers Price Target | A - GuruFocus
Biotech Stock Crashes 50%-Plus. What Happened? - Investor's Business Daily
Aardvark Therapeutics Inc (AARD) Stock Price, Quote, News & History - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
PWS phase III HERO’s journey stalled, Aardvark digs into data - bioworld.com
Oppenheimer Has Lowered Expectations for Aardvark Therapeutics (NASDAQ:AARD) Stock Price - MarketBeat
Aardvark Therapeutics, Chevron, Crowdstrike - TradingView
BofA cuts Aardvark Therapeutics stock price target on trial pause By Investing.com - Investing.com Canada
BofA cuts Aardvark Therapeutics stock price target on trial pause - Investing.com South Africa
Oppenheimer Adjusts Aardvark Therapeutics Price Target to $21 From $35, Maintains Outperform Rating - marketscreener.com
Stock Market Today: S&P 500, Dow, Nasdaq Futures Slide Amid US And Israel 'Operation Epic Furry' Against Iran— HKD, AARD, MDB In Focus (UPDATED) - Benzinga
AARD: Analyst BTIG Lowers Price Target, Maintains Buy Rating | A - GuruFocus
Stifel Nicolaus Downgrades Aardvark Therapeutics to Hold From Buy, Adjusts PT to $6 From $24 - marketscreener.com
HC Wainwright Downgrades Aardvark Therapeutics to Neutral From Buy - marketscreener.com
Aardvark Therapeutics (NASDAQ:AARD) Given New $9.00 Price Target at BTIG Research - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Aardvark Therapeutics' (AARD) "Hold" Rating Reiterated at Stifel Nicolaus - MarketBeat
HC Wainwright Reaffirms Neutral Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Aardvark’s PWS Trial Pause Raises Questions On Safety Edge For Appetite Suppressor - Citeline News & Insights
Aardvark Therapeutics stock price target cut to $9 by BTIG on trial pause - Investing.com Australia
RBC Downgrades Aardvark Therapeutics to Sector Perform From Outperform, Cuts Price Target to $6 From $18, Keeps Speculative Risk - marketscreener.com
Why Is Aardvark Therapeutics Stock Sinking Monday? - Bitget
Morgan Stanley Downgrades Aardvark Therapeutics to Equalweight From Overweight, Cuts Price Target to $7 From $29 - marketscreener.com
AARD Downgraded to Neutral by HC Wainwright & Co. | AARD Stock N - GuruFocus
Stifel Downgrades Aardvark Therapeutics (AARD) and Lowers Price Target | AARD Stock News - GuruFocus
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):